

Amendments to the Claims:

Please amend Claims 91, 102 and 103 as set forth below.

1-90. (Canceled)

91. (Currently amended) A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product consists essentially of at least 80% of white blood cells contained in the sample of cord blood or placental blood, less than all of plasma contained in the sample of cord blood or placental blood, ~~and~~ less than 10% of red blood cells contained in the sample of cord blood or placental blood, ~~and~~ a red blood cell sedimentation reagent that facilitated separation of the red blood cells from the white blood cells contained in the sample of cord blood or placental blood, and wherein the therapeutic product has a volume of 10 milliliters to 20 milliliters.

92. (Canceled)

93. (Previously presented) The therapeutic product of Claim 91, wherein the therapeutic product has an osmolarity of not more than 300 milliosmols.

94-95. (Canceled)

96. (Previously presented) The therapeutic product of Claim 91, wherein the red cell to white cell count is approximately one hundred (100) to one (1).

97. (Previously presented) The therapeutic product of Claim 91, wherein the therapeutic product further consists of an anticoagulant.

98. (Previously presented) The therapeutic product of Claim 97, wherein the anticoagulant comprises Citrate, Phosphate, and Dextrose (CPD).

99. (Previously presented) The therapeutic product of Claim 91, wherein the therapeutic product further consists of a cryoprotectant.

100. (Previously presented) The therapeutic product of Claim 99, wherein the cryoprotectant comprises dimethyl sulfoxide.

101. (Previously presented) The therapeutic product of Claim 99, wherein the cryoprotectant comprises dextran.

102. (Currently amended) A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product comprises at least 80% of white blood cells contained in the sample of cord blood or placental blood, less than all of plasma contained in the sample of cord blood or placental blood, less than 10% of red blood cells contained in the sample of cord blood or placental blood, a red blood cell sedimentation reagent that facilitated separation of the red blood cells from the white blood cells contained in the sample of cord blood or placental blood, and dimethyl sulfoxide diluted to 50% with dextran.

103. (Currently amended) A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product comprises at least 80% of white blood cells contained in the sample of cord blood or placental blood, ~~and~~ less than all of plasma contained in the sample of cord blood or placental blood, and a red

Applicants: Pablo Rubinstein et al.

Serial No.: 09/855,789

Filed: May 15, 2001

Page 4 of 7

blood cell sedimentation reagent that facilitated separation of the red blood cells from the white blood cells contained in the sample of cord blood or placental blood, and wherein the red cell to white cell count is approximately one hundred (100) to one (1).